Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Zymeworks, ProBioGen in Antibody Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Zymeworks, ProBioGen in Antibody Development Pact

To use GlymaxX Technology to enhance antibody-dependent cell-mediated cytotoxicity

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Zymeworks Inc. have entered an agreement under which ProBioGen will complete cell line development of a Zymeworks bi-specific antibody product candidate, applying its GlymaxX Technology to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
 
ProBioGen’s chief scientific officer, Dr. Volker Sandig, said, “We have been working productively with Zymeworks for some time already and look forward to contributing to the success of Zymeworks’ Azymetric™ bi-specific antibody platform. Our proprietary CHO expression platform is ideally suited for the expression of bi-specific antibodies with high purities and expression titers. The implementation of our innovative GlymaxX technology for enhanced cancer cell killing underlines the flexibility of our expression platforms’ tool box approach.”
 
Dr. Ali Tehrani, Zymeworks’ president and chief executive officer said, “We believe that biotherapeutics developed using the Azymetric platform have the potential to create game-changing treatment options for patients with unmet medical needs. Our productive partnership with ProBioGen and their highly skilled team will help advance one of Zymeworks’ therapeutic programs into the clinic. The incorporation of the GlymaxX technology is one of the key components in enhancing the efficacy of this therapeutic candidate.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics